Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER

NCT00585195 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00585195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00585195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 19, 2006
Completion date
January 19, 2022
Enrollment
596 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies except leukemia, non-small cell lung cancer alk-positive, non-small cell lung cancer c-met dependent, non-small cell lung cancer ros marker positive, systemic anaplastic large-cell lymphoma